A Phase Ib/II Randomized Study of BI 836845 in Combination With Exemestane and Everolimus Versus Exemestane and Everolimus Alone in Women With Locally Advanced or Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Xentuzumab (Primary) ; Everolimus; Exemestane
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Boehringer Ingelheim
- 02 Nov 2019 This trial is completed in Austria, France, Ireland, Spain and Sweden, as per European Clinical Trials Database record.
- 01 Mar 2019 Planned End Date changed from 26 Dec 2019 to 12 Nov 2019.
- 17 Dec 2018 Planned End Date changed from 16 Dec 2018 to 26 Dec 2019.